Interní Med. 2002; 4(8): 6-9

Hormonální antikoncepce a tromboembolická nemoc - jak je to ve skutečnosti

MUDr. Petr Dulíček Ph.D, MUDr. prof. MUDr. Ivo Kalousek Jaroslav Malý Ph.D. CSc
II. interní klinika, odd. klinické hematologie FN Hradec Králové

Keywords: Oral contraceptives, venous thromboembolism, inherited thrombophilia.

Published: December 31, 2002  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dulíček P, Kalousek Jaroslav Malý I. Hormonální antikoncepce a tromboembolická nemoc - jak je to ve skutečnosti. Interní Med. 2002;4(8):6-9.

Hormonální antikoncepci užívá více než 100 miliónů žen po celém světě. Přesto, že dnes jsou užívána kontraceptiva s nízkým obsahem estrogenů, riziko žilního tromboembolizmu stále trvá. Riziko žilní trombózy je větší v prvním roce užívání a při užívání hormonální antikoncepce III. generace. Riziko trombózy je dále umocněno přítomností vrozeného trombofilního stavu, ale je závislé na typu protrombotického stavu. Ačkoliv podíl hormonální antikoncepce na incidenci žilní trombózy v populaci je malý, je významným rizikovým faktorem u mladých žen.

ORAL CONTRACEPTIVES AND TROMBOEMBOLIC DISEASE - HOW IS IT IN REALITY?

Oral contraceptives are used over 100 million women worldwide. The risk of venous thromboembolism is still present with current low-dose oral contraceptives. The risk of thrombosis is higher during the first year of use and with the use of third generation of oral contraceptives. The risk of thrombosis is enhanced in the concomittant presence of inherited thrombophilia but this risk depends on the type of prothrombotic abnormality. Even though in absolute terms the contribution to the inci-dence of venous thromboembolism in the population is small, oral contraceptives are major risk factor for venous thrombosis in young women.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Battiger LE, Boman G, Eklung G. Oral contraceptives and thromboembolic disease: effects of low oestrogen content. Lancet 1980; 1: 1097-1101. Go to original source... Go to PubMed...
    2. Bertina RM, Koeleman RPC, Koster T. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67. Go to original source... Go to PubMed...
    3. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third generation progestagen. Lancet 1995; 346: 1593-1596. Go to original source... Go to PubMed...
    4. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM. Hemostasis effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives. Thromb Hemost 1998; 80: 29-34. Go to original source...
    5. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000; 160: 49-52. Go to original source... Go to PubMed...
    6. Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific group. WHO technical report series, No. 877. Geneva. World Health Organization 1998.
    7. Comp PC, Nixon RR, Cooper MR. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984; 74: 2082-2088. Go to original source... Go to PubMed...
    8. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008. Go to original source... Go to PubMed...
    9. De Visser MCH, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor F V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 1271-1276. Go to original source...
    10. Dulíček P, Kalousek I. Hormonální antikoncepce a tromboembolická nemoc na konci tisíciletí. Plánování rodiny a reprodukční zdraví 2000; 3: 60-63.
    11. Egeberg O. Inherited antithrombin III deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516-530. Go to original source... Go to PubMed...
    12. Farmer RDT, Lawrenson RA, Thompson CR. Population-based study of risk of venous contraceptives. Lancet 1997; 349 (9045): 83-88. Go to original source... Go to PubMed...
    13. Gerstman BB, Piper JM, Tomita DK. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991; 133 (1): 32-37. Go to original source... Go to PubMed...
    14. Girolami A, Simioni P, Girolami B. The role of drugs, particularly oral contraceptives, in triggering thrombosis in congenital defects of coagulation inhibitors: a study of six patients. Blood Coag Fibrinol 1991; 2: 673-678. Go to original source... Go to PubMed...
    15. Green D, Maliekel K, Sushko E. Activated protein C resistance in cancer patients. Tromb Haemost 1997; Suppl. 1: 316. Go to original source... Go to PubMed...
    16. Griffin JH, Ewatt B, Zimmerman TS. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 370-373. Go to original source... Go to PubMed...
    17. Guideline: Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114: 512-528. Go to original source... Go to PubMed...
    18. Inmann WHW, Vessey MP. Investigation of death from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age. Br Med J 1968; 193-199. Go to original source... Go to PubMed...
    19. Jick H, Jick SS, Gurewich V. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with different progestagen components. Lancet 1995; 346: 1589-1593. Go to original source... Go to PubMed...
    20. Jordan WM. Pulmonary embolism. Lancet 1965; 232: 155-160.
    21. Kalousek I, Dulíček P. Současné názory na vztah hormonální antikoncepce a venózního tromboembolizmu. Praktická gynekologie 2001; 2: 38-41.
    22. Kluft C, Lansing M. Effect of oral contraceptives on hemostasis variables. Thromb Haemost 1997; 78: 315-326. Go to original source... Go to PubMed...
    23. Koster T, Rosendaal FR, de Ronde H. Venous thrombosis due to a poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-1506. Go to original source... Go to PubMed...
    24. Lewis MA, Heinemann LA, MacRae KD. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observation research. Contraception 1996; 54: 5-13. Go to original source... Go to PubMed...
    25. Linqvist PG, Svensson PJ, Maršál K. Activated protein C resistance (f V Q 506) and pregnancy. Thromb Haemost 1999; 81: 532-537. Go to original source... Go to PubMed...
    26. Martinelli I, Taioli E, Bucciarelli P. Interaction between the G20210A mutation of the protrombin gene and oral contraceptive use in deep venous thrombosis. Arterioscler Thromb Vasc Biol 1999; 19: 700-703. Go to original source... Go to PubMed...
    27. Meade TW, Greenberg G, Thompson SG. Progestagens and cardiovascular reactions associated with oral contraceptives and comparison of the safety of 50-30 microgram oestrogen preparations. Br Med J 1980; 280: 1157-1161. Go to original source... Go to PubMed...
    28. Meijers JCM, Middeldorp S, Tekelenburg W. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI - independent down regulation of fibrinolysis. Thromb Haemost 2000, 84: 9-14. Go to original source... Go to PubMed...
    29. Meinerdi JR, Henkens CMA, Heringa I. Acquired APC resistance related to oral contraceptives and pregnancy and its possible implications for clinical practise. Blood Coag Fibrinol 1997; 8: 152-154. Go to original source... Go to PubMed...
    30. Middeldorp S, Meijers JCM, van den Ende. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost 2000; 84: 4-8. Go to original source... Go to PubMed...
    31. Nordström M, Lindblad B, Berqvist D. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155-160. Go to original source... Go to PubMed...
    32. Pabinger I, Schneider B, and the GTH Study group on Natural Inhibitors. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S- deficiency taking oral contraceptive medication. Thromb Haemost 1994; 71: 548-552. Go to original source... Go to PubMed...
    33. Poort SR, Rosendaal FR, Reitsma PH. A common genetic variation in the 3´ untraslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703. Go to original source...
    34. Rintelen C, Mannhalter C, Ireland H. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1996; 93: 487-490. Go to original source... Go to PubMed...
    35. Rodendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost State of the Art 1999; 82 (No. 2): 610-619. Go to original source...
    36. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Oral contraceptives, hormonal replacement therapy and thrombosis. Thromb Haemost 2001; 86 (State of the Art): 112-123. Go to original source...
    37. Rosendaal FR, Koster T, Vandenbroucke JP. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-1508. Go to original source...
    38. Sartwell PE, Mai AT, Arthes FG. Thromboembolism and oral contraceptives: an epidemiological case-control study. Am J Epidemiol 1969; 90: 365-380. Go to original source... Go to PubMed...
    39. Schwarz HP, Fisher M, Hopmeier P. Plasma protein S deficiency in familial thrombotic disease. Blood 1884; 64: 1297-1300. Go to original source...
    40. Simioni P, Sanson BJ, Prandoni P. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81: 198-202. Go to original source... Go to PubMed...
    41. Spitzer WO, Lewis MA, Heinemann LA. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case - control study. Transnational research group on oral contraceptives and the health of young women. BMJ 1996; 312: 83-88. Go to original source... Go to PubMed...
    42. Tans G, Curvers J, Middeldorp S. A randomized cross-over study on the effects of levonorgestrel-and desogetrel - containing oral contraceptives on the anticoagulation pathways. Thromb Haemost 2000; 84: 15-21. Go to original source... Go to PubMed...
    43. United nations department for Economic and Social Information and Policy Analysis population Division. Levels and trends of contraceptive as assessed in 1994. United Nations New York 1996.47. World Health Organization Effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization collaborative study of cardiovascular disease and steroid hormone contraception. Lancet 1995; 346: 1582-1588.
    44. Vandenbroucke JP, Helmerhorst FM, Briet E. Increased risk of venous thrombosis in oral-contraceptive users who carriers of factor V Leiden mutation. Lancet 1999; 344: 1453-1457. Go to original source... Go to PubMed...
    45. Vasilakis C, Jick SS, del Mar Melero-Montes M The risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 1999; 354: 1610-1611. Go to original source... Go to PubMed...
    46. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 1998; 57: 315-324.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.